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Introduction
Tick-borne encephalitis (TBE) is a pathogenic human infec-
tion caused by the TBE virus (TBEV), a flavivirus, which 
is transmitted by infected ticks and by unpasteurized dairy 
products from infected cows, goats, or sheep. TBE occurs 
focally in the non-tropical Eurasian forest belt with most 
cases occurring in Russia and in Central and Eastern parts of 
Europe. In endemic areas, TBEV is one of the most important 
causes of viral meningitis/encephalitis and is a major public 
health problem.1
Approximately, 10,000–12,000 clinical cases of TBE are 
reported worldwide each year.2-4 In Europe, between 1990 
and 2009, 8,755 cases were reported annually. Of these, 
2,815 cases (33.1%) occurred in Central and Eastern Europe, 
excluding Russia. However, this figure is believed to be under-
estimated, mainly due to insufficient routine diagnostics and 
surveillance.1,5 Overall, in the last three decades, reported 
cases of TBE have increased by 317.8% in Europe and Russia, 
and by 193.2% in Europe alone.1,5,6
The epidemiology of TBE is, however, very focal in nature. 
Even in the most affected regions, the disease is usually lim-
ited to a specific area. As a result, prevalence figures vary con-
siderably, even within countries.
The proportion of ticks infected with TBEV varies mark-
edly in each region. While TBEV prevalence in ticks reaches 
20–40% in highly endemic areas, it can be as low as 0.1–0.5% 
in other areas.2,7 Therefore, seroprevalence data are not suffi-
ciently reliable or meaningful and should be more localized 
to reveal the true epidemiological picture of TBE within the 
affected region. Small rodents can be used as a useful indica-
tor of the circulation of TBE in an area.8 While transmission 
Tick-borne encephalitis (TBE) is a viral neurological zoonotic 
disease transmitted to humans by ticks or by consumption of 
unpasteurised dairy products from infected cows, goats, or 
sheep. TBE is highly endemic in areas of Central and Eastern 
Europe and Russia where it is a major public health concern. 
However, it is difficult to diagnose TBE as clinical manifestations 
tend to be relatively nonspecific and a standardised case 
definition does not exist across the region. TBE is becoming 
more important in Europe due to the appearance of new 
endemic areas.
Few Central European Vaccination Awareness Group 
(CEVAG) member countries have implemented universal vac-
cination programmes against TBE and vaccination coverage is 
not considered sufficient to control the disease. When imple-
mented, immunization strategies only apply to risk groups un-
der certain conditions, with no harmonised recommendations 
available to date across the region. Effective vaccination pro-
grammes are essential in preventing the burden of TBE. This re-
view examines the current situation of TBE in CEVAG countries 
and contains recommendations for the vaccination of children 
and high-risk groups.
For countries at very high risk of TBE infections, CEVAG 
strongly recommends the introduction of universal TBE vac-
cination in children > 1 y of age onwards. For countries with 
a very low risk of TBE, recommendations should only apply to 
those traveling to endemic areas. Overall, it is generally accept-
ed that each country should be free to make its own decision 
based on regional epidemiological data and the vaccination 
calendar, although recommendations should be made, espe-
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approximately 88%, the annual number of clinical TBE cases 
has declined by 90% compared with the prevaccination era.1,2 
However, national vaccination campaigns are not implemented 
in most European countries where TBE is endemic, resulting 
in low vaccine coverage and high disease incidence.1 Defined 
regional guidelines are therefore important for vaccine imple-
mentation and uptake.
The aim of this review is to reinforce existing knowledge 
of TBE burden, highlighting the current situation in Central 
European Vaccination Awareness Group (CEVAG; http://www.
cevag.org/) countries and how CEVAG perceives TBE risk, and 
developing a formal CEVAG guidance statement on TBE vac-
cination. CEVAG consists of regional experts from 12 Central 
European countries: Bulgaria, Croatia, the Czech Republic, 
Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, 
Slovenia and Turkey. The aim of CEVAG is to encourage the 
efficient and safe use of vaccines to prevent, control and, if pos-
sible, eradicate infectious diseases. This will be addressed by rais-
ing awareness of vaccination and by compiling and distributing 
appropriate information. CEVAG is an established voluntary 
association of national representatives and legal entities, which 
shares an interest in promoting vaccination in Central Europe. 
CEVAG is organizationally independent of state administration 
and self-administration bodies, political parties and other civic 
associations and initiatives. The association does, however, coop-
erate with these groups during the realization of common plans 
and promotion of matters of common interest.
The Disease Burden in CEVAG Countries
Currently, TBE is a notifiable disease in 10 of 12 CEVAG mem-
ber countries. In Bulgaria, clinically defined encephalitis cases 
are reportable, irrespective of the cause and in Turkey, very little 
information is available (Table 1).
TBE is considered endemic in many regions within CEVAG 
countries. The Czech Republic, Estonia, Latvia, Lithuania and 
Slovenia have highly endemic areas (incidence > 10 per 100,000 
population). Estonia, Latvia and Lithuania are considered par-
ticularly high risk.6,15 TBE is also an important issue in Poland, 
Slovakia and Hungary.16
In recent decades, the number of TBE cases in CEVAG coun-
tries has increased, which may be in part attributable to the 
introduction of mandatory reporting, better surveillance and 
improved disease diagnosis linked to healthcare improvements. 
The incidence rates of TBE (per 100,000 population) vary sig-
nificantly not only between countries, but also within regions.1
According to a 2011 report published by the World Health 
Organization (WHO), some of the highest rates of TBE are 
being reported in the Baltic states, including Estonia, Latvia 
and Lithuania (from north to south) and Slovenia.2 In 2009, the 
highest rates of TBE were reported in Estonia (18.7/100,000)17 
and Lithuania (17.8),18 followed by Latvia (14.6)19 Slovenia 
(9.90), and Czech Republic (7.8)16 and the lowest rates in 
Hungary (0.60).1 The highest rates of TBE have been reported 
in Latvia: 21.97/100,000 in 2010 and 18.70 in 2011 (as reported 
in November).19 In Slovakia, the rate was 2/100,000 in 2011.20
seasons vary, ticks are most active from early spring to late 
autumn (March to November) and seasonal TBE incidence usu-
ally coincides with increased exposure during this period.9
Three main TBEV subtypes cause the human disease: the 
Western or European subtype, transmitted primarily by the tick 
Ixodes ricinus; the Far-Eastern subtype, transmitted mainly by 
I. persulcatus; and the Siberian subtype, transmitted mostly by 
I. persulcatus. All three subtypes co-circulate in the Baltic region.1,2
TBE Diagnosis and Case Definitions
Following a tick bite, only 10–30% of susceptible cases become 
infected with TBEV and 90% of these develop flu-like symp-
toms.2 The remaining 10% of infections lead to more serious 
illnesses such as meningitis, meningoencephalitis and menin-
goencephalomyelitis.2 TBE can be fatal, with 1–2%, 6–8% 
and 20% of patients reportedly dying from the European, and 
Siberian and Far-Eastern subtypes, respectively. Up to 46% of 
TBE patients suffer from long-term sequelae.10
Etiological diagnosis of TBE requires laboratory confirmation 
because clinical manifestations tend to be relatively nonspecific 
and are not usually sufficient for diagnosis.11 Moreover, there is 
no clear internationally standardized case definition of TBE, and 
apart from Austria, no clear perception of TBE risk.1
At-Risk Populations
TBE is more common in males than females.2 All age groups 
can be affected but case distributions vary by region. People liv-
ing in rural areas or at altitudes below 1400 m are at increased 
risk of TBE compared with those in urban areas. Most infections 
are caused by tick bites in forested areas. Professional occupation 
(military personnel, farmers and forestry workers) and/or inter-
est in recreational outdoor activities in endemic areas increases 
exposure to tick bites. Moreover, new endemic areas appear as 
changes in climate occur and recreational activities increase. As 
a result, TBE is a growing problem for unvaccinated travelers in 
areas where the disease is endemic.4,12
The incidence and severity of TBE are highest in persons aged 
> 50 y with increase starting from 40 y, but a small number of 
cases occur in children and adolescents, in whom the signs of 
meningitis are dominant.1 In children aged < 7 y, TBE tends to 
be less severe and permanent sequelae are uncommon;13 how-
ever, there are few high quality TBE studies in children.4,12 Most 
TBEV infections occur through a tick bite although a small 
number are associated with the consumption of unpasteurized 
milk products.2,14
The risk of TBE infection can be reduced by the use of per-
sonal measures in endemic areas, such as the wearing of appropri-
ate protective clothing and daily inspection for tick bites. These 
preventive measures are, however, not sufficiently reliable and 
vaccination is the most effective way to prevent TBE infection.
TBE vaccines, manufactured in Austria and Germany, pro-
vide protection against European TBEV subtypes and have 
been highly successful over recent decades.1,2 In Austria, where 
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of TBE compared with other CEVAG countries. Bulgaria does 
not have a specific surveillance system for TBE. Encephalitis 
cases are registered in bulk as seasonal encephalitides with no 
separate record of TBE cases, and as a result, very few human 
cases have been reported. Four laboratory confirmed cases of 
TBE have been reported in the last two years.21 AlthoughTBE is 
not endemic in Bulgaria, physicians should be aware of this infec-
tion in patients with manifestations of viral meningitis.
Croatia
In Croatia, TBE was first described in 1953 and since 2007 it 
has been an obligatory reportable disease. However, the report-
ing of cases still depends on the “goodwill” of clinicians. From 
In some countries, such as the Czech Republic, Hungary and 
Slovenia, TBE is clinically defined as aseptic meningitis, menin-
goencephalitis and/or meningoencephalomyelitis. In most coun-
tries, TBE is routinely diagnosed by detecting specific antibodies 
in serum and cerebrospinal fluid (CSF) using the enzyme-linked 
immunosorbent assay (ELISA).
Bulgaria
In Bulgaria, clinically defined encephalitis cases are reportable, 
irrespective of the cause. Although TBEV has been found near to 
natural foci, the epidemiological significance of TBE is negligible 
(A. Mangarov, unpublished data). The geographical characteris-
tics of Bulgaria probably contribute to the atypical epidemiology 




Natural foci Case definition
Incidence rates 
(cases per 100,000 
population)a
Bulgaria No
Of negligible epidemiological  
significance
No official TBE case definition. 
Encephalitis cases are reported in bulk 





Northwestern and eastern regions











Endemic in most areas
Highly endemic areas include: 
Southern Bohemia, Berounka
Clinical symptoms (signs of aseptic men-
ingitis/meningoencephalitis with proven 
neuroinfection in CSF) 




Estonia Yes, since 1949
Endemic
Highly endemic areas include: west-
ern (Pärnumaa, Läänemaa), and east-
ern (Ida-Virumaa) regions, Saaremaa 
and Hiiumaa (Western islands) and 
southeastern region (Polvamaa, 
Tartumaa)
Possible: typical case history  
(biphasic infection) with epidemiological 
links (e.g., tick attack). 
Confirmed: clinically compatible case 
with positive laboratory tests. 
Laboratory testing: ≥ 4-fold increase in 
antibody titer in paired serums or IgM 






Hungary Yes, since 1977
Endemic
Highly endemic areas include: 
western region and along the river 
Danube (Zala, Somogy and Vas), 
northern region (Nógrád) and around 
Lake Balaton
Aseptic meningitis, encephalitis or 
meningoencephalomyelitis laboratory 
confirmed. 
Hospitalization is not necessary for diag-
nosis
Until 1996: 1.3–3.8 
1997–2000: 0.67
Latvia Yes, since 1955
Endemic
Highly endemic areas include: north-
western regions (near the coast) of 
Talsu and Ventspils









2011: 97.21  
(Kuldīgas region)
CSF, cerebrospinal fluid; N/A, Not available; PCR, polymerase chain reaction; TBE, tick-borne encephalitis; TBEV, tick-borne encephalitis virus.  
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city. Recently, two new natural foci have emerged in the central 
mountainous region, south of the river Sava.23,24
According to seroepidemiology data collected over a 7-y period 
(2002–2008), a seroprevalence rate of 14.4/100,000 (range 1.6–
66.6) was reported across all Croatian counties.23 Another study, 
1999–2009, the Croatian Institute for Public Health reported 
between 11–44 cases of TBE annually.22
Croatia has natural foci of TBE in the northwestern region, 
between the rivers Sava and Drava, and in the northeastern 
region, across a small area on the western outskirts of Osijek 




Natural foci Case definition
Incidence rates 
(cases per 100,000 
population)a
Lithuania Yes, since 1960
Endemic
Highly endemic areas include: Kaunas, 
Panevėžys and Šiauliai
No official case definition, but reported 






Poland Yes, since 1970
Endemic in much of the country
Highly endemic areas include: north-
eastern (Bialystock) and southwestern 
regions
Possible: clinically compatible case 
and onset of illness during periods of 
increased tick activity (April–November).
Probable: clinically compatible case and 
increased probability of infection during 
previous 6 weeks (living in or visiting to 
endemic areas), and demonstration of 
specific IgM antibodies in serum, with no 
history of vaccination against any flavivi-
ral disease during the previous 3 mo 
Confirmed: clinically compatible case and 
demonstration of specific IgM and IgG 
antibodies in serum, or demonstration 
of intrathecal synthesis of specific IgM or 
IgG antibodies, detection of specific anti-
TBEV antibodies by neutralization test, 




Romania Yes, since 1996
Endemic emergent course and natu-
ral foci in full territorial expansion
Highly endemic areas include: Tulcea 
district, Transylvania at the base of 
the Carpathian Mountains and the 
Transylvanian region
No official case definition. 
Clinical manifestation and diagnostic 
tests
N/A
Slovakia Yes, since 1950
Endemic
Highly endemic areas include: Trencín 
region in the northwest
New foci identified in the East






2011: 2.0 (8.35 in the 
Trenčín region)
Slovenia Yes, since 1977
Endemic
Highly endemic areas include: 
Gorenjska and Koroska
Confirmed TBE case: fever, clinical signs/
symptoms of meningitis or meningoen-
cephalitis, elevated CSF cell count (> 5 x 
105 cells/l), and serum IgM antibodies to 





2006: 33.4  
(aged 55–64 y)
Turkey No
Very scarce data on TBEV and no  
published diagnosed/reported cases
No official case definition N/A
CSF, cerebrospinal fluid; N/A, Not available; PCR, polymerase chain reaction; TBE, tick-borne encephalitis; TBEV, tick-borne encephalitis virus.  
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country.30 A peak incidence was noted in 1997 (27.8/100,000) 
and in 1998 (27.0).30 From 2006–2010, the rate ranged from 
6.7–15.0/100,000 with an average of 156 cases reported each 
year.30 In 2011, the rate increased to 18.7/100,000 (250 cases 
in a population of 1.34 million).17 Main drivers of the increased 
rate of TBE include climatic and socio-economic changes such 
as agricultural reforms, and increased mushroom and berry har-
vesting and recreational outdoor activities.
In the period 1999–2008, the highest morbidity was reported 
among people aged > 40 y. This is equivalent to 53.5% (lowest 
rate of 42.1% in 1999, highest rate of 66.5% in 2004) of the 
entire infected population.30 The proportion of children aged 
0–14 y in the TBE-infected population was 16.0% (lowest rate 
of 8.8% in 2004, highest rate of 23.5% in 2000).30 Among chil-
dren aged < 3 y, three cases of TBE were reported (0.2% of 
total cases).30 Overall, the proportion of hospitalized TBE cases 
ranged from 75.6–96.7%.30 During this period, a peak inci-
dence was observed between May and September.30
In 2010, the highest rates of transmission were reported in 
the western (Pärnumaa, Läänemaa), eastern (Ida-Virumaa) and 
southeastern (Polvamaa, Tartumaa) regions of Estonia, and in 
the Western islands (Saaremaa and Hiiumaa).17
From 2006–2008, the proportion of ticks carrying TBEV 
varied, according to the region, from 0.2% in Puhtu (western 
Estonia) to 6.4% in Järvselja (southern Estonia).17 Both vectors 
of the TBEV Western or European subtypes, I. ricinus and I. 
persulcatus, co-circulate in Estonia. Recently, the Far Eastern 
subtype was identified in western Estonia.31 All three known 
subtypes have now been observed in Estonia.31
In 2005, the consumption of unpasteurized goat’s milk con-
tributed to nearly 30% of all nationwide TBE cases (two unre-
lated outbreaks with 37 cases).1 Veterinary and Food Board 
investigations confirmed the presence of TBEV antibodies in the 
serum of goats from milk suppliers.32 In 2009, three cases were 
linked to the consumption of goat’s milk.
Hungary
TBE is endemic in Hungary. Approximately two-thirds of the 
population live in high-risk areas of the western and northern 
(Nógrád) regions, along the river Danube (Zala, Somogy and 
Vas) and around Lake Balaton.1,15
In 1985 over 350 cases were reported to the National Centre 
for Epidemiology. Up until 1996, annual rates of TBE ranged 
from 1.3–3.8/100,000 with 3 to 7 fatal cases/year6,15 and from 
1997–2000, rates decreased dramatically (0.67/100,000). The 
number of cases gradually stabilized at 50–70 cases/year in 2009 
and 2010, with no fatalities during the past 3 y, possibly due to 
the availability of TBE vaccines.33
New high-risk areas are being found at high altitudes 
(> 1,000 m) and, in 2007, 25 TBE cases were linked to the 
consumption of raw goat’s milk.34 A recent cluster of four TBE 
cases was identified in October 2011.35 Initial investigations 
revealed a possible association with consumption of unpasteur-
ized cow’s milk. Altogether 11 cases (seven confirmed and four 
suspected) were identified. Customers who had consumed the 
conducted within a defined area along the river Sava, reported 
that 4.41% of forestry workers were IgG-seropositive while none 
of the volunteer controls tested positive.25 Further data collected 
over a 5-y period (2006–2011) at the University Hospital for 
Infectious Diseases (UHID) in Zagreb, showed an average of 20 
TBE cases per year and an annual incidence of 1.1/100,000 [G. 
Tešovic, unpublished data]. Most cases reported in this study 
were adults (86.7% aged > 18 y vs 13.3% of children and adoles-
cents aged 1–18 y), with a peak incidence in June (20 cases) and 
July (26 cases). The similar age and seasonal case distributions 
were observed in the endemic regions of Koprivnica (Northern 
Croatia) and Osijek (Eastern Croatia).26,27 Although some dif-
ferences in clinical severity have been observed between Eastern 
Croatia and the rest of the country, mortality is generally low (< 
3.3%). However, permanent neurological sequelae were present 
in 17.1% of adult patients.27,28
The Czech Republic
TBE has been recognized as a disease in the Czech Republic 
since 1948, but cases have only been reported since 1971. Two 
reporting systems have been established in the country.
TBE is endemic in most of the Czech Republic, but some 
areas have a much higher risk than others. The Southern 
Bohemia region and Prague are the two most affected areas, but 
TBE foci have also been identified in the southern Moravia and 
highland region.29 In the east of the country, there has been a 
high reported incidence near Olomouc city.29 The high number 
of cases reported in Prague has been associated with residents 
traveling to areas of greater risk and being diagnosed with TBE 
upon their return.
In 2000, 719 cases were reported (7.2/100,000), peaking in 
2006 with 1029 cases (10/100,000).16 In 2007, 546 cases were 
reported (5.42/100,000), increasing to 861 in 2011 (8.6/100,000). 
Currently, more than 130 cases of TBE are diagnosed in Czech 
children annually [R. Chlibek, unpublished data].
Although some children die of TBE, higher case-fatality rates 
are reported in adults. Up until 2007, TBE fatality rates ranged 
between 1.44–4.61% among older age groups (> 65 y) compared 
with 0.48% among children aged 1–4 y [Source: IPH-CEM 
(EPIDAT), by courtesy of C. Beneš, National Health of Public 
Health, Prague].
In the Czech Republic, TBE has a seasonality trend with 
most cases reported between April and December.29 Most cases 
were reported in July (> 100 cases each year from 1971–2000, > 
150 from 2001–2005 and > 250 in 2006) and September (> 250 
in 2006) [Source: SZÚ-CEM (ISPO and EPIDAT), by courtesy 
of C. Beneš, National Health of Public Health, Prague].
Estonia
Estonia has one of the highest rates of TBE in Europe. This 
disease has been reportable since 1949 and there has been an 
upward trend in new cases over the past 30 y.
In 1980, TBE was only reported in the southern regions 
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TBE cases were reported in 2008 and 2009 (605 and 612 cases, 
respectively) compared with the previous 5 y between 2004–
2008 (range 220–462, 6.9–13.5/100,000).6 Four fatal cases of 
TBE were notified in 20036 and none in 2011.39
In Lithuania, no recent seroprevalence data exist. In one study 
conducted in 2000, 2.9% (43 of 1488) of healthy individuals 
were found to be positive to TBE infection.37
In Lithuania, TBE affects 1.4 times as many males as females, 
and people from rural areas are 1.7 times more likely to be affected 
than those living in urban areas.38 The latter has remained con-
stant over the past 10 y. It has been estimated that approximately 
40% of all TBE cases are among retired and unemployed adults38 
and this has remained relatively constant over recent years. One 
reason could be that these people are more likely to collect mush-
rooms and berries, which can serve as an additional source of 
income. The rate of TBE is approximately 2- to 3-fold higher in 
adults than in children (0–18 y of age).38 Typically, 20% of all 
TBE cases in Lithuania are reported in people aged > 60 y and 
< 10% are from children. In 2003, the 40–49 age group made 
up nearly 20% of the total, although the increased rate of TBE 
affected all age groups.38
In Lithuania, the tick season is from late March until mid-
November. In 2003, most TBE cases were reported in September 
and October.38 In 2009, 447 cases were documented between 
August and October, and in 2010 more than 200 cases were 
reported in October.39
In Lithuania, I. ricinus is the only vector of TBE and the 
Western TBEV is the only subtype found in all districts.37 
However, the proportion of Lithuanian ticks infected with TBE 
is still unknown.40 Although TBE is normally transmitted by tick 
bite, in 2003 22 cases of TBE from four different clusters were 
acquired from unpasteurized goat’s milk.6
Poland
TBE is endemic in most of Poland with the highest rates reported 
in the northeastern and southwestern regions.1,6,15 Approximately 
80% of cases have been reported around Bialystock, an area 
located in the northwestern provinces, adjacent to Lithuania and 
Belarus. The districts close to the Czech Republic in the south-
western region are another important focus of the disease.6 In 
2008, new endemic foci were identified in the north-western 
provinces of Poland where very few cases have been reported pre-
viously (1970–2005).6
Since 1993, between 100–350 cases have been reported annu-
ally;6 339 (0.89/100,000) in 2003 and 335 (0.52/100,000) in 
2009.6,15
Romania
In Romania, TBE is endemic and natural foci are in full ter-
ritorial expansion.41 Risk areas are focused in the Tulcea district, 
Transylvania, at the base of the Carpathian mountains and the 
Transylvanian Alps.1,6 However, the nationwide annual rate of 
TBE has not been published and the relative risk of contracting 
this disease is unknown.
unpasteurized cow’s milk had more than 2-fold increased risk 
for TBE, however this finding was not statistically significant.
Latvia
TBE has been notifiable in Latvia since 1955.36 Although risk 
areas for TBE are spread throughout the country, the highest rate 
was reported in 2011 near the northwest coastal regions of Talsu 
and Ventspils (26.4/100,000). In 2011, a rate of 97.21/100,000 
was reported in Alsunga city in the Kuldīga region.19
Between 1990–2000, Latvia had the highest rates of TBE 
in the world, ranging from 8 to 53 cases/100,000 in 1993 
and 1995, respectively.6,36 After 1999, the rate decreased to 
6.2/100,000 in 2005 thanks to intensive vaccination activity.1,6 
Between 2005–2009, 199 cases were reported on average each 
year.19 However, since 2009, the number of cases has started to 
increase.
In 2010, there was a dramatic increase in TBE infections, with 
494 reported cases (21.97/100,000), many (137 cases) of whom 
were aged > 60 y, unvaccinated, of low income and involved in 
berry and mushroom picking activities. The 2010 figure repre-
sents a 148% increase in TBE cases compared with that reported 
in previous years (2005–2010), and a 51% increase compared 
with 2009.19
In Latvia, ticks carry a higher TBEV load than in other at-risk 
countries. Latvia also has the highest reported rates of TBE trans-
mitted by dairy products, mainly goat’s milk, which accounts for 
5% of total cases.1 In 2010, 18 TBE cases were reported in children 
(0–18 y of age), which may reflect high vaccination coverage.
Both I. ricinus and I. persulcatus are present in Latvia, but each 
has a different seasonal activity. While I. ricinus has two seasonal 
activity peaks in western and central Latvia, I. persulcatus has 
only one spring peak and predominates in the eastern region.36
Lithuania
Lithuania has the highest rate of TBE of all Baltic countries1 
where it is recognized as one of the most important causes of 
central nervous system (CNS) diseases in adults. TBEV is highly 
endemic across much of the country and 3% of the population 
is thought to have been exposed.6,15 In some areas, a rate of TBE 
as high as 100/100,000 has been reported.6 Northern and cen-
tral Lithuania account for 80% of cases reported annually.6,15 In 
some of these high-risk areas—mainly the Kaunas, Panevėžys 
and Šiauliai counties—rates of TBE are > 40/100,000.15 In 2003, 
the highest rate was reported in Panevėžys with 100/100,000.6 
In the Kaunas county, TBE infections accounted for more than 
50% of all CNS infections.37
In 2003, the rate was twice that reported in the previous 
decade,6,37 the highest recorded rate since notification began in 
1960, and was the highest of all the Baltic countries.6,38 This 
is thought to be due to the availability of improved diagnostic 
methods since 1993, but the high incidence in 2003 may also be 
linked to the high number of ticks observed in that particular 
year.38 On average, 422 cases of TBE were reported in the 7-y 
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Northern Anatolia. TBEV IgG positivity was detected in 2.9% 
(8/273) and 1.9% (47/2454) of people in the Sinop and Anatolia 
regions, respectively.45,46 In the Anatolia survey, risk factors for 
tick-borne infections were identified in 53% of individuals posi-
tive for TBEV. One sample from the Zonguldak province in the 
Black Sea region of Turkey was confirmed to possess neutralising 
antibodies. However, most cases should be considered as ‘prob-
able’ since the majority of results obtained were not confirmed by 
additional testing.
The presence of TBEV in Sinop and the Black Sea region 
should be identified as these regions are located near to known 
TBEV endemic areas. Overall, the epidemiology of TBEV activ-
ity in Turkey needs further assessment and the benefits of vac-
cination for the general population, risk groups or travelers to 
endemic regions must be considered.
Current Available TBE Vaccines in Europe
For TBE, licensed vaccines include an Austrian vaccine (FSME–
Immun® also known as TicoVac® in all Baltic and Scandinavian 
countries; Baxter) and a German vaccine (Encepur®; Novartis 
Vaccines), and which available throughout Europe.
Other licensed vaccines not available in Europe include 
two Russian vaccines, TBE-Moscow® (available in Russia, 
Kazakhstan and Ukraine) and EnceVi® (Russia only).
TBE Vaccine Immunogenicity and Effectiveness
No clinical trials have been conducted on the efficacy of TBE 
vaccines, but the effectiveness and safety of current vaccines has 
been proven in a number of observational studies.11 In Austria, 
high vaccination coverage has lead to a significant decrease in 
TBE incidence and a protection rate over 95%.47 TBE vaccine 
failure infections are reported rarely and mainly occur in older 
groups.11 Very few failure cases have been reported in individuals 
aged < 25 y, with only two cases occurring in children.11 A 2009 
study in the Slovenian region of Gorenjska reported a higher 
number of TBE cases than expected among vaccinated individu-
als (4 patients with a history of TBE vaccination from a total 
of 63 TBE cases).11 However, according to the surveillance case 
definition for TBE and the case classification for vaccine failures, 
only one of four cases previously vaccinated was reported to be a 
verified failure case.11
The Austrian and German vaccines are well tolerated and effi-
cacious for individuals aged > 1 y,1 and both Russian vaccines for 
those aged > 3 y.1 All of the currently available vaccines appear 
to protect against all TBEV subtypes circulating in Europe and 
Asia.2
TBE transmitted by unpasteurised milk, such as the outbreaks 
in Hungary, could be effectively prevented by vaccinating people 
and/or dairy animals, although it is not clear yet how long the 
immunity against TBEV persists in animals.48
General Dosage and Administration Schedules
In 2001–2006, an epidemiological survey of TBEV infec-
tion was performed in 1669 individuals from 11 Transylvanian 
counties.41 In the general population, the seroprevalence rate was 
estimated to be 0.6%, but even higher rates were found in at-risk 
populations: 5.8% in those living around natural foci and up to 
41.5% in those with known occupational risks. A seroprevalence 
rate of 11.6% was reported in the domestic habitat of former 
patients with TBE-Central European Encephalitis.41 TBEV was 
the most common cause of acute viral meningitis (14.1%).41
Slovakia
Most parts of Slovakia are thought to be endemic,1 with 50–90 
TBE cases reported annually. Between 1998–2007, on average, 67 
(range 46–92) cases were reported annually;1,6 91 (1.7/100 000) 
in 2006 and 57 (1.1/100 000) in 2007.20 This compares with 108 
cases (2.0/100,000) in 2011.20 In the same year, 50 cases of TBE 
(8.35/100,000) were reported in the northwest Trenčín region, 
along the river Váh near the Czech Republic.42 New foci have 
been identified in eastern Slovakia, a region traditionally thought 
to be free of TBEV.6 Some of the reported cases were attributed 
to the consumption of raw homemade goat’s and sheep’s milk.6 
In the Trencín region, 16 cases were reportedly caused by unpas-
teurised milk products between 2008–2010.6,42,43
Slovenia
Since 1977, notification of TBE cases and deaths has been man-
datory in Slovenia.11 TBE is endemic throughout the country.6 
Surveillance data collected over the past 20 y (1991–2011) found 
the highest rates of TBE in the Gorenjska and Koroska regions, 
with annual rates of 57.2 and 76.9/100,000, respectively.11,44
Between 2001–2005, the 5-y average was 261 cases,1,6 peak-
ing at 445 in 2006.6 From 2000–2009, incidence rates ranged 
between 7.6–18.6/100,000.11
In Slovenia in the last decade, there has been an age distribu-
tion shift of TBE to the older age groups, resulting in the highest 
age-specific incidence rates in those aged 55–64 y (33.4/100,000 
in 2006).44
I. ricinus is the main vector of TBEV in Slovenia, with a 
reported prevalence of 0.43% and 0.54% in 2005 and 2006, 
respectively.7 Infection rates of TBEV in ticks were significantly 
correlated with TBE incidence rates in Slovenian patients in 
selected areas. The TBEV in ticks was confirmed to be geneti-
cally related to the TBEV in the Slovenian patients.7
Turkey
In Turkey, very limited data are available on TBE and no human 
cases have been officially reported; Turkey is not a TBE endemic 
country.1,6,45 As in other European countries, I. ricinus is the most 
common vector, especially in the coastal regions.46
Although no nationwide studies have been published, two 
regional surveys have commented on the TBEV exposure among 
residents of rural areas in Sinop (a province located on the coast 
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reimbursed by the state.36 The vaccination rate for the national 
population was 39% in 2009 and 41% in 2010, which is the 
highest after Austria. This has resulted in a significant reduc-
tion of TBE cases among children living in highly endemic areas; 
12.5% in 2001 to 3.6% in 2010.19
Existing Recommendations for TBE Vaccination
WHO recommendations. As TBE incidence varies consider-
ably between and within geographical regions, WHO recom-
mends that public vaccination strategies should be based on 
risk assessments conducted at country, regional or even district 
level.1,2 Therefore, before deciding on the most appropriate pre-
ventive measures, it is important to establish adequate TBE case 
reporting.2
In areas where the disease is highly endemic (≥ 5 cases/100,000 
per year), implying that there is a high individual risk of infec-
tion, WHO recommends vaccination of all age groups, including 
children.50 Where the rate of TBE is moderate or low (5-y inci-
dence of < 5/100,000 per annum), or is limited to specific areas 
or outdoor activities, vaccination should target individuals in the 
most severely-affected cohorts.2
The WHO also recommends TBE vaccination of travelers to 
rural and forested areas up to altitudes of 1,400 m.2,50
Although few recent cost–effectiveness evaluations exist, 
Austrian estimates suggest that TBE vaccination is cost effective, 
at least in those countries with high and widespread endemicity.1 
In Slovenia, for example, a country with high TBE incidence and 
low vaccine coverage, the current vaccination program against 
TBE was found to be cost-effective for adults from a healthcare 
payer’s perspective.51 Vaccination was cost saving from a societal 
perspective due to avoidance of costs associated with TBE infec-
tion. As TBE places a huge burden on healthcare resources (e.g., 
acute and long-term treatment), cost-effectiveness is expected to 
be strongly influenced by efficient targeting of vaccination pro-
grammes and vaccine pricing.
Consensus and conflicts in CEVAG country recommen-
dations. It is evident that each CEVAG country has a differ-
ent approach. Overall, vaccination is recommended for people 
at high risk of TBEV infection, such as those residing, working 
or traveling in endemic areas. Mandatory vaccination is being 
implemented for some of these groups in several CEVAG coun-
tries, but there is still no consensus across the region.
Existing guideline recommendations from CEVAG countries. 
An overview of TBE vaccine recommendations across CEVAG 
countries is presented in Table 2. There is a lot of variation from 
country to country and sometimes within the country. Latvia is 
the only CEVAG country with a national universal TBE vaccina-
tion program; most other countries in the region have programmes 
linked to specific conditions. Slovenia does not have a universal 
national program and TBE vaccination is only recommended for 
high-risk groups. Romania and Turkey have not implemented any 
national programmes, policies or recommendations for TBE.
TBE vaccination is not universally covered or reimbursed in 
any of the CEVAG countries. Currently, the Czech Republic, 
European manufacturers (Austrian and German vaccines) rec-
ommend three doses for complete priming. The second dose is 
given 1–3 mo after the first, and the third is given 9–12 mo after 
the second. The first booster is recommended 3 y after priming. 
For both vaccines, the manufacturer’s recommended intervals 
and subsequent booster doses vary by age and should be given 
every 5 y for those aged < 60 y and every 3 y for those aged ≥ 
60 y.1
Accelerated or rapid schedules, used in emergency situations, 
are based mainly on reduced intervals between the first two 
doses. The accelerated schedule for the Austrian vaccine recom-
mends the first and second doses on days 0 and 14, respectively, 
and the third dose 5–12 mo after the second. The rapid schedule 
for the German vaccine recommends doses on days 0, 7 and 21, 
with a fourth dose 12–18 mo after the third.1
Vaccine Coverage in CEVAG Countries
Most CEVAG countries have not implemented a universal vac-
cination program for TBE, and for those that have, vaccination 
rates differ widely. Furthermore, in many countries, vaccine 
coverage is considered to be too low to effectively control the 
disease.15
In Croatia, although there are no national recommendations 
for TBE, vaccination of at-risk groups (mainly forestry work-
ers in the northern Koprivnica region) has reduced the num-
ber of reported TBE cases 3-fold (304 in 1979–1988 vs. 90 in 
1999–2007).26
In the Czech Republic, as traditional endemic areas expand, 
vaccination is recommended not only for residents, but also for 
travelers and retired persons who visit for recreational purposes.15 
In Southern Bohemia, one-third of the population is vaccinated, 
particularly children and younger adults.15 Vaccination cover-
age fluctuates from 12 to 23% in the other parts of the Czech 
Republic. In Estonia in 2010, 18,000 people (10% of the popula-
tion) were vaccinated, including 5561 children. In the same year, 
15,274 people were reported to have been revaccinated includ-
ing 2784 children aged 1–14 y, 976 adolescents aged 15–17 y 
and 11,514 adults.17 In Hungary, although TBE has been rec-
ognized as an occupational hazard since the late 1990s, vaccine 
coverage remains low, covering only 5–15% of the total popula-
tion.15 Despite TBE being endemic across much of Poland, only 
0.34% of the population were vaccinated between 1999–2007, 
with more than half of those living in the northeastern, highly 
endemic regions.15
Slovenia has one of the highest reported rates of TBE, but 
vaccination uptake remains low (only 12.4% of those aged ≥ 15 
y in 2007).49 Vaccination coverage should be improved to reduce 
disease burden and morbidity. This could be accomplished by 
offering compulsory vaccination within health insurance in addi-
tion to intensive vaccine promotion, thereby reducing the social 
inequality to access.44
In Lithuania, vaccination coverage is considered to be too 
low to control the disease. In Latvia, approximately 22% of chil-
dren had been vaccinated by the end of 2010, most (77%) of 
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Table 2. TBE vaccination in CEVAG countries1-2,15-16
Country Available National vaccination program Vaccination coverage
Bulgaria
No TBE vaccine  
registered
No (optional)  
Only recommended for travelers abroad
Unknown
Croatia
Yes, Austrian and 
German vaccines 
(both registered but 
only Austrian cur-
rently available)
No (optional) – vaccination is on an ‘individual basis’  
Only recommended for residents in endemic areas and those visit-
ing endemic areas (for recreation)  




Yes, Austrian and 
German vaccines
No, but recommended for infants, children and adults living in or 
traveling to highly endemic areas
As traditionally endemic areas expand, vaccination is increasingly 
recommended to adults/elderly living in or traveling to these 
endemic areas, for outdoor activities, forestry and agricultureal 
workers
Reimbursement of the third dose of the vaccine only
2007: 16% (nationwide), 29% (Southern 
Bohemia), and 27% (Prague)
High in children but low in elderly
Estonia
Yes, Austrian and 
German vaccines
No, but recommended to all individuals aged > 1 y
Recommended for travelers visiting endemic areas
No vaccine reimbursement is available for the general population
Free for risk groups (foresters, irrigators, military personnel) – vac-
cination is covered by the employer
10% (nationwide) – increasing due to 
Health Protection Agency campaigns 
and pharmaceutical companies
2010: 18,000 people vaccinated (5561 
children) and 15,274 revaccinated
Hungary
Yes, Austrian and 
German vaccines
Yes: mandatory for people with extensive exposure to ticks in 
rural areas (e.g., forestry workers and farmers since 1998, hikers 
and campers)
Recommended for everyone
Offered free for residents of highly endemic areas




Yes, Austrian and 
German vaccines
Yes, for children (since 2007) and adolescents living in endemic 
areas
Offered free (since 2010) for orphans/children without parental 
care vaccination and children living in highly endemic areas
Mandatory for high risk groups and/or individuals expecting to 
have high occupational exposure (e.g., forest workers and military 
personnel for whom vaccination is paid by employers)
Strongly recommended for adults
Children: 22% (nationwide) and up to 
77% (highly endemic areas)
In highly endemic areas, vaccination 
has reduced child morbidity from 
12.5% in 2001 to 3.6% in 2010
The vaccination rate in the whole 
population was 39% in 2009
Lithuania
Yes, Austrian and 
German vaccines
No (optional)
Recommended > 1 y of age, but full cost is paid by the patient
Some employers provide vaccination (e.g., forest workers)
Vaccines are given on a private basis only
Recommended for travelers
Vaccination rates in Lithuania are very 
low
Approximately 20,000 doses of vac-
cines are used every year
Poland
Yes, Austrian and 
German vaccines
No national TBE vaccination policy implemented, but recom-
mended for residents of endemic areas, particularly for military 
personnel, border guards, fire fighters, farmers and tourists – TBE 
vaccination is not universally reimbursed
Mandatory for forestry workers (since 1994) – reimbursed by the 
employer
Not officially reported
1999: 7500 vaccine doses
2008: 30,800 vaccine doses
2011: 20,000 vaccine doses
1999-2007: 0.34% (nationwide, 
although more than half living in the 
northeastern region)
Romania
Yes, German child 
and adult vaccines 
(both registered)
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there are various recommendations or mandatory programmes 
for high risk groups, endemic exposure and other specific condi-
tions. In many countries, vaccination strategies are based on local 
endemic situations, provincial budgets and financial resources.3
Recommendations for TBE vaccination have existed for many 
years in various European countries. However, these recommen-
dations are not generally followed, including in endemic CEVAG 
countries. Better compliance with these recommendations could 
be achieved through encouraging national TBE awareness cam-
paigns and distribution of educational materials and resources 
for the general public. Increasing the awareness of TBE among 
all physicians and healthcare workers is vital, so that they can 
remind patients to get vaccinated if they either live in an endemic 
area, or are traveling to one.15
TBE is not fully reimbursed by national healthcare systems 
in any of the CEVAG countries except for some specific popula-
tion subgroups (e.g., in Latvia, it is offered free for all orphans 
and children living in highly endemic areas). In highly endemic 
areas, vaccination should be available for all age groups, as recom-
mended by the WHO, leading to some form of reimbursement. 
In the Czech Republic, little or no direct support is available from 
state institutions for vaccinations in highly endemic areas and 
in children and adolescents nationwide (e.g., reimbursement of 
one dose by larger healthcare insurance companies), and this may 
have contributed to the rising incidence of TBE.29
Vaccine coverage has a major influence on disease incidence. 
Although TBE cannot be completely eliminated from endemic 
areas, in Austria, large-scale vaccination campaigns have proven 
highly effective in reducing disease burden. Latvia is the only 
CEVAG country to have a large-scale vaccination campaign for 
all age groups.52
Furthermore, data on vaccination coverage are based solely on 
the number of vaccination doses sold annually and do not reflect 
the percentage of the population vaccinated.16 In this situation, 
therefore, vaccine coverage should be compared carefully with 
incidence rates.
Estonia, Hungary, Latvia, Lithuania and Poland have started to 
reimburse for TBE vaccination, but only for specific groups.1
CEVAG guidance statement. TBE vaccine should be offered 
to children > 10 y of age in countries with low endemic risk, and 
from 12 mo of age in high endemic risk countries. TBE vacci-
nation should also be recommended to those people, regardless 
of age, traveling from non-endemic areas to endemic areas even 
where local prevelance is low (e.g., Austria and its neighboring 
countries have low prevalence rates due to vaccination, but the 
endemicity in ticks remains high). However, vaccination should 
be offered all year round to indivduals aged > 12 mo living in 
highly endemic areas. Overall, it is accepted that CEVAG coun-
tries should be free to make their own decisions based on epide-
miological data and vaccination calendars, but recommendations 
should be made for endemic areas with outdoor activities and for 
those traveling to and from endemic areas.
Discussion
In most CEVAG countries, there is no clear perception of the 
risk of TBE. Since TBE incidence varies considerably between 
geographical areas, vaccination strategies should be based on the 
specific risk of each country, appropriate to the local endemic 
level. Therefore, an epidemiological survey is paramount before 
deciding on the most appropriate vaccination policy. A stan-
dardised case definition of TBE is essential to ensure that epide-
miological data are gathered correctly, regardless of whether or 
not the disease is highly prevalent.16 European consensus is also 
necessary to guarantee the comparability of cases and vaccine 
failures.11 Furthermore, establishing surveillance at the national 
and European level is fundamental for the monitoring and evalu-
ation of disease burden, the impact of vaccination, vaccine effec-
tiveness and an early warning to change the vaccination schedule 
when necessary.11
TBE vaccination programmes are not implemented univer-
sally by any of the governments of CEVAG countries however, 
Table 2. TBE vaccination in CEVAG countries1-2,15-16
Country Available National vaccination program Vaccination coverage
Slovakia
Yes, Austrian and 
German vaccines
National TBE vaccination policy and recommendation implement-
ed only for high-risk occupational groups
Mandatory for staff working in TBE testing laboratories
Recommended for forestry workers, farmers, surveyors, geolo-
gists, mountain huts and cableway staff, police officers, military 
personnel and railway workers
Unknown
Slovenia
Yes, Austrian  
(mainly) and 
German vaccine
National TBE vaccination policy (follows general dosage and 
administration schedules from western manufacturers) and rec-
ommendation implemented only for high-risk groups
Mandatory (since 1986) for high-risk workers
Mandatory (since 1990) for students at high risk
Recommended (since 1991) for people living in or traveling to 
highly endemic areas, including children aged > 1 y
12.4% (nationwide) in 2007:
3.2% (high-risk workers)
2.3% (students at high risk)
2.2% (military personnel)
4.6% (people vaccinated for ‘other 
reasons’)
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Currently, there is no cure for TBE and treatment is symp-
tomatic with the use of antipyretic and anti-inflammatory medi-
cation.1 Patients with severe neurologic manifestations have to be 
closely monitored.1 Vaccination or other prophylactic measures 
are not recommended after a tick bite.1 Since TBE has a relatively 
short incubation period, starting vaccination after a tick bite may 
not provide sufficiently high levels of neutralising antibody to 
protect the individual.1 Very limited clinical data exist support-
ing the use of active postexposure prophylaxis (PEP) using anti-
TBEV immunoglobulins. There is the theoretical concern that 
PEP could result in antibody-dependent enhancement of the dis-
ease, resulting in higher morbidity.1 Although application of PEP 
was withdrawn from the European market in the late 1990s, it is 
still being used in Russia.53
An important target for vaccination should be the older age 
groups, as the disease tends to be more serious in those aged ≥ 
50 y. Many studies have shown that both Western vaccines show 
effective immune responses in children and adults, but none have 
been conducted on the primary response in those aged ≥ 50 y. 
In the elderly population, however, both Western vaccines show 
relatively good boosting responses54,55 with relatively low break-
through rates.56,57 Nevertheless, older persons (aged > 60 y) face 
the risk of becoming seronegative earlier because of the lower 
antibody titer achieved immediately after the booster.1 For exam-
ple, in the Czech Republic, the increase of recreational outdoor 
activities in newly high-risk areas has resulted in more TBE cases 
being detected among the elderly, in whom the disease course is 
more serious.15 Despite this, vaccination rates among older age 
groups (≥ 50 y) remain low in the Czech Republic.15
TBE is becoming all the more important because it is now 
being reported in previously non-endemic areas. In recent years, 
drivers for increased incidence include climatic (warmer climates 
where ticks live all year round) and socio-economic changes (rec-
reational activities in endemic areas and changes in land use).58-61 
This is true in Lithuania where new TBE cases are being reported 
in previously non-endemic areas. In Latvia, the marked decrease 
in TBE morbidity among children in 2010 was significantly cor-
related with the implementation of a TBE vaccination program 
in high-risk areas in 1994.
Both the Austrian and the German TBE vaccines seem to be 
interchangeable for boosting or for completion of previous vacci-
nation series.62,63 Recent clinical data show that they may also be 
conditionally interchangeable during primary vaccination with 
conventional schedules.64 However, data are still lacking and 
thus, a change of vaccines is only acceptable after careful con-
sideration and then only in specific cases, e.g., vaccine shortage.65
To our knowledge, no clinical studies have been published 
indicating that neonates or infants (< 6 mo) are passively pro-
tected against TBEV infection by neutralizing antibodies from 
previously infected mothers, but this protection has been demon-
strated with other flaviviruses, such as the dengue virus.66
TBE burden in CEVAG countries can only be reduced if there 
is a standardised European case definition for the disease. Only 
then can epidemiological data be collected and vaccine effective-
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